Clinical Trial: A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282353) titled 'A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA' on Nov. 21.

Brief Summary: A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA).

Study Start Date: Dec. 10

Study Type: INTERVENTIONAL

Condition: Primary Biliary Cholangitis

Intervention: DRUG: 2mg CS0159

Oral QD

DRUG: Placebo

Oral QD

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Cascade Pharmaceuticals, Inc

Published by HT Digital Content Services with perm...